RL/RS & NE SERIES
SUSTAINED RELEASE FORMULATION

Understanding of human physiology and pathophysiology of various diseases have paves a way for development of various drug delivery system. It is now understood that the drug need not be release immediately after consumption. The sustain drug release can control the disease progress effectively.

DRUGCOAT polymers belonging to RL/RS and NE series can be used for time controlled drug delivery systems.

Product Information

DRUGCOAT SERIES MONOGRAPHS PHYSICAL FORM DISSOLUTION PROPERTIES
DRUGCOAT RL 100 USP/NF: Ammonio Methacrylate Copolymer, Type A
Ph. Eur.: Ammonio Methacrylate Copolymer, Type A
Granules pH-independent swelling
DRUGCOAT RL PO Powder
DRUGCOAT RL 12.5 Organic Solution 12.5%
DRUGCOAT RS 100 USP/NF: Ammonio Methacrylate Copolymer, Type B
Ph. Eur.: Ammonio Methacrylate Copolymer, Type B
Granules
DRUGCOAT RS PO Powder
DRUGCOAT RS 12.5 Organic Solution 12.5%
DRUGCOAT NE 30D USP/NF: Ethyl Acrylate And Methyl Methacrylate Copolymer Dispersion
Ph. Eur.: Polyacrylate Dispersion 30%
Aqueous Dispersion 30%
  • For Sustain Release of API's.
  • Customized release profiles
  • Prolongation of effective plasma level
  • Reduction of total dose
  • Reduce risk of dose dumping
  • Reduce toxicological effects of API's
  • Reduction of Administration frequency
  • Increase patient compliance

Aqueous Dispersion: 60 kg net in HDPE Carboy.
Powder/ Granules: 10 kg net in Paper fiber Drum with polyethylene lining.
Organic Solution: 25kg net in DRUM.

Store at controlled room temperature. (USP, General Monograph)